RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Hubei Minkang Pharmaceutical Stock

Hubei Minkang Pharmaceutical Stocks 2024

Hubei Minkang Pharmaceutical Stocks

52.19 M

Ticker

HBMK

ISIN

US44352W1018

In 2024, Hubei Minkang Pharmaceutical had 52.19 M outstanding stocks, a 19.27% change from the 43.76 M stocks in the previous year.

The Hubei Minkang Pharmaceutical Stocks history

YEARNUMBER OF STOCKS (undefined USD)
201352.19
201243.76
201136.15
20107.65
20097.05
20086.98
200716.88
200616.88

Hubei Minkang Pharmaceutical shares outstanding

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Hubei Minkang Pharmaceutical earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Hubei Minkang Pharmaceutical's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Hubei Minkang Pharmaceutical’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Hubei Minkang Pharmaceutical's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Hubei Minkang Pharmaceutical Aktienanalyse

What does Hubei Minkang Pharmaceutical do?

Hubei Minkang Pharmaceutical Ltd is a Chinese pharmaceutical company that was founded in 1988. Since its establishment, the company has specialized in the development, production, and sale of medicines, particularly traditional Chinese medicines. The company is based in Xianning City, Hubei Province, and employs over 1,000 staff, including over 400 technicians and researchers. It is a leading manufacturer of medicines in China and has a good reputation in the national and international markets. Hubei Minkang Pharmaceutical has a wide business model that specializes in the development and marketing of medicines in various areas. These include: - Traditional Chinese Medicine: Traditional Chinese Medicine (TCM) is one of the company's specialties. TCM is a holistic approach that focuses on the body's natural healing powers. It involves the use of plants, minerals, and animal products to treat diseases and ailments. The company develops and produces a variety of TCM products that are highly valued by Chinese society. - State-of-the-Art Medicines: The company has also invested in modern medicines in recent years and has a specialized research and development department to develop these products. The portfolio also includes impressive developments in cancer therapy and treatment options for cardiovascular diseases. - Veterinary Medicine: Hubei Minkang Pharmaceutical Ltd also produces a wide range of products used in veterinary medicine. This includes remedies for parasites, antibiotics, and vitamins. - Research and Development: The company has established itself as an innovation driver through investment in the research and development of medicines. Hubei Minkang Pharmaceutical Ltd has been awarded with high-quality assurance and boasts a modern production facility that is standardized at the international level. The company has also received certifications from global institutions such as Good Manufacturing Practice (GMP). This ensures that all products are of the highest quality, safety, and efficacy. The company is committed to achieving its self-set corporate goals in a sustainable manner, thus creating a sense of shared responsibility towards the environment and society. Overall, Hubei Minkang Pharmaceutical Ltd is a company that focuses on the development, production, and sale of medicines, particularly traditional Chinese medicine. It has established itself as a successful player in the national and international markets through its specialized divisions and modern manufacturing processes. Hubei Minkang Pharmaceutical ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Hubei Minkang Pharmaceutical's Shares Outstanding

Hubei Minkang Pharmaceutical's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Hubei Minkang Pharmaceutical’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Hubei Minkang Pharmaceutical’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Hubei Minkang Pharmaceutical’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Hubei Minkang Pharmaceutical stock

How many stocks are there of Hubei Minkang Pharmaceutical?

The current number of stocks of Hubei Minkang Pharmaceutical is 52.19 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Hubei Minkang Pharmaceutical are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Hubei Minkang Pharmaceutical evolved in recent years?

The number of shares of Hubei Minkang Pharmaceutical has increased by 19.27% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Hubei Minkang Pharmaceutical as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Hubei Minkang Pharmaceutical?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Hubei Minkang Pharmaceutical pay?

Over the past 12 months, Hubei Minkang Pharmaceutical paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Hubei Minkang Pharmaceutical is expected to pay a dividend of 0 USD.

What is the dividend yield of Hubei Minkang Pharmaceutical?

The current dividend yield of Hubei Minkang Pharmaceutical is .

When does Hubei Minkang Pharmaceutical pay dividends?

Hubei Minkang Pharmaceutical pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Hubei Minkang Pharmaceutical?

Hubei Minkang Pharmaceutical paid dividends every year for the past 0 years.

What is the dividend of Hubei Minkang Pharmaceutical?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Hubei Minkang Pharmaceutical located?

Hubei Minkang Pharmaceutical is assigned to the 'Health' sector.

Wann musste ich die Aktien von Hubei Minkang Pharmaceutical kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Hubei Minkang Pharmaceutical from 10/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/3/2024.

When did Hubei Minkang Pharmaceutical pay the last dividend?

The last dividend was paid out on 10/3/2024.

What was the dividend of Hubei Minkang Pharmaceutical in the year 2023?

In the year 2023, Hubei Minkang Pharmaceutical distributed 0 USD as dividends.

In which currency does Hubei Minkang Pharmaceutical pay out the dividend?

The dividends of Hubei Minkang Pharmaceutical are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Hubei Minkang Pharmaceutical

Our stock analysis for Hubei Minkang Pharmaceutical Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hubei Minkang Pharmaceutical Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.